Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

prostate cancer

- PMLiVE

Major prostate cancer screening trial launched in UK

The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men

- PMLiVE

Physician-driven, AI-supported: addressing the clinical trial access gap

To open up more clinical paths for patients, HCPs need simpler search tools, better access to information and integrated referral systems that fit into their clinical workflows

- PMLiVE

Bioxodes appoints Philippe Monteyne as new chairman of the board

The appointment comes as the company releases phase 2a data for its intracerebral haemorrhage treatment

Woman holding weight loss injection

Why patients drop out of weight management trials and what you can do about it

Discover the key barriers to retention in obesity and weight-management trials and explore actionable, patient-centered strategies to improve engagement, outcomes, and data reliability.

Cuttsy + Cuttsy

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

The authorisation approximately triples the number of patients eligible to receive the therapy

- PMLiVE

ICR researchers uncover genes responsible for tumour progression in prostate cancer

The findings could pave the way for new treatment approaches that improve patient outcomes

- PMLiVE

Prostate cancer blood test with ‘unprecedented accuracy’ cuts biopsies by 50%

There is currently no national screening programme for prostate cancer in the UK

- PMLiVE

ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

The research could pave the way for the development of new drugs that prevent drug resistance

- PMLiVE

AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

More than 52,000 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer

Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis

- PMLiVE

J&J’s Erleada shows overall survival benefit in head-to-head prostate cancer study

Approximately 300,000 new cases of the disease are diagnosed in the US every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links